Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a lighter sedative dose keep patients calm after nasal surgery?

NCT ID NCT07740655

Symptom relief Sponsor: Jeju National University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This trial tests whether a low dose of the sedative remimazolam can prevent emergence agitation—confusion and restlessness during recovery from anesthesia—after nasal surgery. The standard dose can cause excessive sleepiness and brain wave suppression, so researchers want to see if a lower dose works just as well with fewer side effects. Adults aged 18-79 undergoing nasal surgery under sevoflurane anesthesia will receive either a low or standard dose of remimazolam at the end of surgery, and their recovery will be closely monitored.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
remimazolam
What this could lead to
If low-dose remimazolam works as well as the standard dose, it could offer a safer way to prevent post-surgery agitation, reducing excessive sedation and brain activity suppression.
What could go wrong
This is a small, single-center trial, and the lower dose might not be as effective. There's also a risk of allergic reactions or other side effects from the drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 138 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 79 years. * Scheduled to undergo elective nasal surgery under sevoflurane-based general anesthesia at Jeju National University Hospital. * Able to provide written informed consent. Exclusion Criteria: * Contraindications to remimazolam. * History of allergy or hypersensitivity to benzodiazepines. * Inability to provide informed consent due to cognitive impairment. * Preexisting psychiatric disorders. * History of alcohol or substance abuse. * Inability to assess the Riker Sedation-Agitation Scale (SAS). * Body mass index (BMI) \> 40 kg/m².

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Emergence agitation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Emergence Delirium

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Emergence agitation General anesthesia Nasal surgical procedures

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Jeju National University Hospital

    Jeju City, Jeju-do, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.